Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014;2014(1):18.
doi: 10.1186/1687-9856-2014-18. Epub 2014 Sep 15.

Successful use of long acting octreotide in two cases with Beckwith-Wiedemann syndrome and severe hypoglycemia

Hiba Al-Zubeidi  1 , Michael E Gottschalk  1 , Ron S Newfield  1
Affiliations
Case Reports

Successful use of long acting octreotide in two cases with Beckwith-Wiedemann syndrome and severe hypoglycemia

Hiba Al-Zubeidi et al. Int J Pediatr Endocrinol. 2014.

Abstract

Introduction: Hyperinsulinism associated with Beckwith-Wiedemann syndrome (BWS) can occur in about 50% of cases, causing hypoglycemia of variable severity. Parenteral use of octreotide may be indicated if unresponsive to diazoxide. There is limited data on use of octreotide in BWS.

Objective: Chart review describing 2 cases with BWS and hypoglycemia treated with long acting Octreotide as a monthly injection.

Cases: We describe two unrelated females born large for gestational age found to have clinical features consistent with BWS, who developed severe hypoglycemia. Genetic diagnosis of BWS was confirmed. The first patient was born at 37 weeks and developed hypoglycemia shortly after birth. She was initially started on diazoxide but developed pulmonary congestion and was therefore switched to depot octreotide (LAR). She maintained euglycemia with LAR. In the second patient (born at 26-4/7 weeks), onset of hypoglycemia was delayed till 11 weeks of age due to hydrocortisone (indicated hemodynamically) and continuous feeding, and was partially responsive to diazoxide. She was switched to octreotide 4 times daily, treated till at age 18 months. Despite frequent feeds, she required treatment again between ages 4-6.5 years, initially with diazoxide but due to severe hypertrichosis she was switched to LAR with an excellent response. Both patients treated with LAR for over two years achieved euglycemia above 70 mg/dl and had normal height gain, without side effects.

Conclusion: Successful treatment of hypoglycemia can be achieved and maintained with LAR in infants and children with BWS who are either resistant or cannot tolerate diazoxide.

Keywords: Beckwith-Wiedemann syndrome; Hyperinsulinism; Hypoglycemia.

PubMed Disclaimer

References

    1. Weng E, Mortier G, Graham J. Beckwith-Wiedemann syndrome. Clin Pediatric (Phila) 1995;34:317–326. doi: 10.1177/000992289503400605. - DOI - PubMed
    1. Spivey PS, Bradshaw WT. Recognition and management of the infant with Beckwith-Wiedemann Syndrome. Adv Neonatal Care. 2009;9(6):279–284. doi: 10.1097/ANC.0b013e3181c2003f. quiz 285. - DOI - PubMed
    1. Munns CFJ, Batch JA. Hyperinsulinism and Beckwith-Wiedemann Syndrome. Arch Dis Child Fetal Neonatal Ed. 2001;84:F67–F69. doi: 10.1136/fn.84.1.F67. - DOI - PMC - PubMed
    1. Elliott M, Bayly R, Cole T, Temple IK, Maher ER. Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clin Genet. 1994;46(2):168–174. - PubMed
    1. Cooper WN, Luharia A, Evans GA, Raza H, Haire AC, Grundy R, Bowdin SC, Riccio A, Sebastio G, Bliek J, Schofield PN, Reik W, Macdonald F, Maher ER. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2005;13(9):1025. doi: 10.1038/sj.ejhg.5201463. - DOI - PubMed

Publication types

LinkOut - more resources